Anna FärnertJohan UrsingThomas TolfvenstamJosea RonoLillemor KarlssonElda SparrelidNiklas LindegårdhKarolinska InstitutetKarolinska University HospitalMahidol UniversityNuffield Department of Clinical Medicine2018-06-112018-06-112012-05-28Malaria Journal. Vol.11, (2012)147528752-s2.0-84861366881https://repository.li.mahidol.ac.th/handle/20.500.14594/14318Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment. © 2012 Färnert et al.; licensee BioMed Central Ltd.Mahidol UniversityImmunology and MicrobiologyMedicineArtemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from TanzaniaArticleSCOPUS10.1186/1475-2875-11-176